Investigators from the International Headache Genetics Consortium, a world-wide collaboration of researchers, have identified the first-ever genetic risk factor associated with common types of migraine. Researchers looked at genetic data of more than 50,000 people and found new insights into the triggers for migraines attacks, which commonly begin in puberty and but tend to affect people aged between 20 to 45 years of age. Migraine affects approximately one in six women and one in 12 men.
“This is a major stride in migraine science,” said David W. Dodick, president of the American Headache Society, and professor of neurology at the Mayo Clinic College of Medicine, and the director of the Headache Program in Phoenix, Arizona. Underscoring the significance of the findings, Dr. Dodick said, “It is the first study to identify a genetic risk factor for the common subtypes of migraine, and provides some support for the general concept of migraine as a state of brain hyperexcitability. It also supports previous research findings on the potential role of glutamate in migraine , as well novel glutamate modulating drugs that are currently being tested in migraine. Further work may provide insight into the precise molecular mechanism(s) of migraine as well as future targets for novel therapies.”
The team found that patients with a particular DNA variant on Chromosome 8 between two genes — PGCP and MTDH/AEG-1 — have a significantly greater risk for developing migraine. It appears that the associated DNA variant regulates levels of glutamate — a chemical, known as a neurotransmitter, which transports messages between nerve cells in the brain. Prevention of the build up of glutamate at the synapse (space between nerve endings) may provide a promising target for novel therapeutics to ease the burden of the disease, according to Dr. Dodick. Although researchers have in the past described genetic mutations giving rise to rare and extreme forms of migraine, this is the first time a team has identified a genetic variant giving rise to the common forms of the condition.
The American Headache Society® (AHS) is a professional society of health care providers dedicated to the research and treatment of headache and face pain. www.americanheadachesociety.org The American Migraine Foundation (AMF) is a non-profit foundation of AHS. The mission of AMF is to support innovative research that will lead to improvement in the lives of those who suffer from migraine and other disabling headaches. www.americanmigrainefoundation.org
To arrange an interview with Dr. Dodick please contact:
Martha Cid/Cynthia Goldstein
212-539-3258 / 212-539-3273
Joyce Yaeger
631-597-6099
a mobile natural pain management system ::: !!!
With a Pran Yantra or Tesla Purple Energy Plate ,You wouldn’t have to rush to HOSPITAL for a sudden Migraine, Back Pain, Sprain BURN, Spondalities, Fibromyalgia, Headache, Stomach ache, toothache , stress, fatigue, trauma, depression, menstrual cramps & pains. Helps in all Mental problems & cures INSOMNIA from day one. It is a mobile natural pain management system which provide relief within 20 minutes in any kind of pain related emergency. Simply place the plate on the painful area. No body contact is necessary.
It is based on the scientific principles of Light, Colours, Sounds & Vibrations. Aluminium plates are treated with different colours till it assumes Purple Shade. Exposure to high frequency sounds & a few other procedures creates an energy field which is capable to programme the irregular vibratory frequency of our body N keeps u away from all Computer Related Injuries too. Designed for life -long use on Humans, animals & plants.
This photo album helps out the first time user of these magical plates.http://s642.photobucket.com/albums/uu148/teslaindia_photos/
Could you define the source of your statistics?
According to the original Nature Genetics article “8% of males and 17% of females in the European population” suffer from migraines.
Interestingly, according to a review in the National Geographic, the genetic regional variation in question occurs in 25% of migraine sufferers as well as 19% of the general european population studied. Surely this suggests a more complex interplay of molecular interactions and regulatory mechanisms affecting the pathophysiology observed.